Physician profile
Manuel Jimenez
NPI 1619412350
$3,253.44
in general payments reported to CMS, 2019-2025
24 companies · $884 in 2025
The $884 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $612 · 2022: $717 · 2023: $642 · 2024: $397 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.01 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $479.50 | 2021-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.52 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $208.50 | 2021-2023 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $205.78 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $180.33 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $179.43 | 2021-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $159.87 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.80 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $140.38 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $118.64 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $107.83 | 2021-2022 | |
| Dexcom, INC. | $89.22 | 2021-2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $65.62 | 2021-2022 | |
| Pfizer INC. | $58.15 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $52.47 | 2023 | Myrbetriq, Veozah |
| Kyowa Kirin, INC. | $51.79 | 2025 | |
| Esperion Therapeutics, INC. | $29.02 | 2021 | |
| Alk-Abello, INC | $24.33 | 2024 | Ragwitek, Grastek, Odactra |
| Xeris Pharmaceuticals, INC. | $18.88 | 2023 | Gvoke Hypopen |
| Becton, Dickinson and Company | $13.65 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.13 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.47 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.